EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Canbridge Pharmaceuticals's enterprise value is HK$158.8 Mil.
Canbridge Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-373.4 Mil. Therefore, Canbridge Pharmaceuticals's EV-to-EBITDA for today is -0.43.
The historical rank and industry rank for Canbridge Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
HKSE:01228'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.54 Med: -0.41 Max: 0.51
Current: -0.43
During the past 5 years, the highest EV-to-EBITDA of Canbridge Pharmaceuticals was 0.51. The lowest was -3.54. And the median was -0.41.
HKSE:01228's EV-to-EBITDA is ranked worse than 100% of 451
companies
in the Biotechnology industry
Industry Median: 9.54
vs HKSE:01228: -0.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Canbridge Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, Canbridge Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's EV-to-EBITDA falls into.
Canbridge Pharmaceuticals's current Enterprise Value is HK$158.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-373.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Canbridge Pharmaceuticals's PE Ratio for today is calculated as:
Canbridge Pharmaceuticals's share price for today is HK$0.34.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.974.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Canbridge Pharmaceuticals EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Canbridge Pharmaceuticals (HKSE:01228) Business Description
Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01228 has been successfully added to your 